+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PARP Inhibitors Drug Therapy Market - Global Forecast 2026-2032- Product Image
PARP Inhibitors Drug Therapy Market - Global Forecast 2026-2032- Product Image
New

PARP Inhibitors Drug Therapy Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 183 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674431
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The PARP Inhibitors Drug Therapy Market is rapidly evolving, driven by the intersection of targeted therapies, biomarker advances, and heightened demands for clinical value and access. This report equips senior decision-makers with up-to-date insights and actionable strategies to navigate a shifting landscape defined by scientific and commercial transformation.

Market Snapshot: PARP Inhibitors Drug Therapy

The PARP Inhibitors Drug Therapy Market grew from USD 7.80 billion in 2025 to USD 8.33 billion in 2026 and is projected to continue expanding at a CAGR of 9.88%, reaching an estimated USD 15.11 billion by 2032. Market momentum reflects demand for targeted oncology solutions, increasing adoption of combination regimens, and regulatory support for biomarker-driven treatment frameworks.

Scope & Segmentation Analysis

This report delivers a comprehensive segmentation across all relevant dimensions of the PARP inhibitors space, enabling data-driven commercial and clinical decision-making:

  • Indication: Breast Cancer (with detailed subgroups such as hormone receptor positive and triple negative), Ovarian Cancer (segmented by BRCA mutation and HRD status), Pancreatic Cancer (advanced and early stage), and Prostate Cancer (metastatic and non-metastatic).
  • Drug Type: Niraparib, olaparib, rucaparib, and talazoparib highlight differentiation in safety, scope, and combination applications.
  • Line of Therapy: First line, maintenance, and subsequent lines support clinical positioning and market entry strategies.
  • Treatment Setting: Inpatient and outpatient care environments impact resource allocation and administration approaches.
  • End User: Hospitals, retail pharmacies, and specialty clinics define distribution models and engagement tactics.
  • Distribution Channel: Hospital, online, and retail pharmacies shape supply-chain logistics and accessibility.
  • Therapy Type: Combination and monotherapy strategies influence trial design and patient management.
  • Patient Age Group: Adults and elderly populations inform safety, adherence, and monitoring strategies.
  • Regions: Americas, Europe Middle East & Africa, and Asia-Pacific feature diverse regulatory, reimbursement, and adoption patterns.

Key Takeaways for Decision-Makers

  • The clinical application of PARP inhibitors has extended across multiple tumor types, driven by advances in precision medicine and DNA repair pathway insights.
  • Biomarker-enabled patient stratification and companion diagnostics are refining therapeutic targeting, increasing the efficiency of clinical programs and supporting regulatory approvals.
  • Combination regimens with immune checkpoint and targeted kinase inhibitors are reshaping therapy paradigms, contributing to more complex evidence generation and value demonstration needs.
  • Payers and procurement teams are demanding robust real-world outcome data, leading manufacturers to invest in adaptive trial designs and long-term evidence collection outside traditional studies.
  • Lifecycle strategies—including label expansion, new dosing paradigms, and ongoing safety optimization—are necessary for portfolio differentiation as competition grows.
  • Regional regulatory environments and healthcare infrastructure variation require tailored access and partnership models, particularly in Asia-Pacific and multi-country scenarios.

Tariff Impact on Global Supply Chains

The effects of U.S. tariffs introduced in 2025 have influenced PARP inhibitor supply chains by raising costs for active pharmaceutical ingredients and manufacturing inputs. As a result, companies are accelerating nearshoring, building procurement redundancy, and re-evaluating vendor networks to preserve continuity and manage volatility. These changes are affecting global distribution, trial logistics, and pricing negotiations, with stakeholders prioritizing scenario planning and collaborative contracting to balance risks and maintain patient access.

Methodology & Data Sources

This analysis utilizes a robust methodology integrating primary interviews with clinical experts, payers, and commercial leaders alongside secondary research from peer-reviewed journals, regulatory bodies, and clinical registries. Triangulation, source verification, and quality reviews ensure that findings accurately reflect current market realities and development trends.

Why This Report Matters

  • Enables executive teams to align clinical, diagnostic, and commercial strategies for competitive advantage in a complex, segmented oncology landscape.
  • Equips stakeholders to anticipate regulatory, operational, and reimbursement shifts affecting both market entry and sustained access.
  • Supports risk management and scenario-based planning around policy, trade, and supply-chain challenges.

Conclusion

PARP inhibitor therapy continues to evolve through targeted innovation, integrated diagnostics, and agile strategies that respond to scientific and market dynamics. This report provides senior leaders with a roadmap to sustain growth and patient benefit amid changing regulatory and operational environments.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. PARP Inhibitors Drug Therapy Market, by Drug
8.1. Niraparib
8.2. Olaparib
8.3. Rucaparib
8.4. Talazoparib
9. PARP Inhibitors Drug Therapy Market, by Indication
9.1. Breast Cancer
9.2. Ovarian Cancer
9.3. Pancreatic Cancer
9.4. Prostate Cancer
10. PARP Inhibitors Drug Therapy Market, by Line Of Therapy
10.1. First Line
10.2. Maintenance
10.3. Subsequent Line
11. PARP Inhibitors Drug Therapy Market, by Treatment Setting
11.1. Inpatient
11.2. Outpatient
12. PARP Inhibitors Drug Therapy Market, by Therapy Type
12.1. Combination Therapy
12.2. Monotherapy
13. PARP Inhibitors Drug Therapy Market, by Patient Age Group
13.1. Adults
13.2. Elderly
14. PARP Inhibitors Drug Therapy Market, by End User
14.1. Hospitals
14.2. Retail Pharmacies
14.3. Specialty Clinics
15. PARP Inhibitors Drug Therapy Market, by Distribution Channel
15.1. Hospital Pharmacies
15.2. Online Pharmacies
15.3. Retail Pharmacies
16. PARP Inhibitors Drug Therapy Market, by Region
16.1. Americas
16.1.1. North America
16.1.2. Latin America
16.2. Europe, Middle East & Africa
16.2.1. Europe
16.2.2. Middle East
16.2.3. Africa
16.3. Asia-Pacific
17. PARP Inhibitors Drug Therapy Market, by Group
17.1. ASEAN
17.2. GCC
17.3. European Union
17.4. BRICS
17.5. G7
17.6. NATO
18. PARP Inhibitors Drug Therapy Market, by Country
18.1. United States
18.2. Canada
18.3. Mexico
18.4. Brazil
18.5. United Kingdom
18.6. Germany
18.7. France
18.8. Russia
18.9. Italy
18.10. Spain
18.11. China
18.12. India
18.13. Japan
18.14. Australia
18.15. South Korea
19. United States PARP Inhibitors Drug Therapy Market
20. China PARP Inhibitors Drug Therapy Market
21. Competitive Landscape
21.1. Market Concentration Analysis, 2025
21.1.1. Concentration Ratio (CR)
21.1.2. Herfindahl Hirschman Index (HHI)
21.2. Recent Developments & Impact Analysis, 2025
21.3. Product Portfolio Analysis, 2025
21.4. Benchmarking Analysis, 2025
21.5. AbbVie Inc.
21.6. Amgen Inc.
21.7. Artios Pharma Ltd.
21.8. Astellas Pharma Inc.
21.9. AstraZeneca plc
21.10. Bayer AG
21.11. BeiGene, Ltd.
21.12. Biogen Inc.
21.13. Bristol-Myers Squibb Company
21.14. Checkpoint Therapeutics, Inc.
21.15. Clovis Oncology, Inc.
21.16. Daiichi Sankyo Company, Limited
21.17. Eisai Co., Ltd.
21.18. Eli Lilly and Company
21.19. F. Hoffmann-La Roche Ltd.
21.20. Genentech, Inc.
21.21. GlaxoSmithKline plc
21.22. Guardian Therapeutics Inc.
21.23. IMPACT Therapeutics
21.24. JEIL PHARMACEUTICAL CO., LTD.
21.25. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
21.26. Johnson & Johnson Services, Inc.
21.27. Karyopharm Therapeutics Inc.
21.28. Kyowa Kirin Co., Ltd.
21.29. Merck & Co., Inc.
21.30. Merck KGaA
21.31. Myriad Genetics, Inc.
21.32. Novartis AG
21.33. Olympus Corporation
21.34. ONO PHARMACEUTICAL CO., LTD.
21.35. Pfizer Inc.
21.36. Repare Therapeutics Inc.
21.37. Ribon Therapeutics, Inc.
21.38. Sanofi S.A.
21.39. SyntheX Inc.
21.40. Takeda Pharmaceutical Company Limited
21.41. Teva Pharmaceutical Industries Ltd.
21.42. Zai Lab Limited
List of Figures
FIGURE 1. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 15. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 16. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 118. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 119. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 120. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 121. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 122. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 123. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 136. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 137. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 138. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 139. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 140. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 141. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 155. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 156. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 157. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 158. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 159. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 160. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 164. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 165. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 166. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 167. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 168. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 169. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 182. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 183. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 184. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 185. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 186. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 187. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 189. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 191. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 192. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 193. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 194. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 195. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 196. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 200. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 201. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 202. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 203. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 204. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 205. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 211. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 212. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 213. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 216. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 217. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
TABLE 219. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 220. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 221. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 222. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 223. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 224. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this PARP Inhibitors Drug Therapy market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Artios Pharma Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeiGene, Ltd.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Checkpoint Therapeutics, Inc.
  • Clovis Oncology, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Guardian Therapeutics Inc.
  • IMPACT Therapeutics
  • JEIL PHARMACEUTICAL CO., LTD.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Novartis AG
  • Olympus Corporation
  • ONO PHARMACEUTICAL CO., LTD.
  • Pfizer Inc.
  • Repare Therapeutics Inc.
  • Ribon Therapeutics, Inc.
  • Sanofi S.A.
  • SyntheX Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zai Lab Limited

Table Information

Report AttributeDetails
No. of Pages183
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 8.33 Billion
Forecasted Market Value ( USD ) by 2032 $ 15.11 Billion
Compound Annual Growth Rate9.8%
Regions CoveredGlobal
No. of Companies Mentioned39

Related Topics

Related Reports

Poly ADP-Ribose Polymerase (PARP) Inhibitors - Global Strategic Business Report - Product Image

Poly ADP-Ribose Polymerase (PARP) Inhibitors - Global Strategic Business Report

  • Report
  • 284 Pages
  • Global
From
Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025 - Product Image

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025

  • Report
  • 200 Pages
  • Global
From
PARP Inhibitor Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

PARP Inhibitor Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 76 Pages
  • Global
From
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025 - Product Image

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Poly Adp-Ribose Polymerase (Parp) Inhibitor Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Poly Adp-Ribose Polymerase (Parp) Inhibitor Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.